Science News

... from universities, journals, and other research organizations

Potential New Treatment Target Identified for Melanoma Skin Cancer

Aug. 15, 2012 — New research from Western University has identified a potential new target for the treatment of melanoma, the deadliest of all skin cancers.


Share This:

Silvia Penuela and Dale Laird have discovered a new channel-forming protein called Pannexin (Panx1) that is expressed in normal levels on the surface of healthy skin cells. But they found, in melanoma, Panx1 is over-produced to a pathological level.

The research is published in the August 17th issue of the Journal of Biological Chemistry.

Malignant melanoma only accounts for four per cent of all skin cancers, and yet it's responsible for 79 per cent of skin cancer-related deaths. The World Health Organization says there are 200,000 cases of melanoma diagnosed each year and 65,000 melanoma-related deaths (2000 statistics).

"We think this over-production of Panx1 enables the melanoma to become very aggressive. The cells have these extra Panx1 channels and they can leave the primary tumor and invade other tissues," explained Laird, a Professor in the Department of Anatomy and Cell Biology.

"And when you find a protein that is highly up-regulated in a disease cell such as a melanoma, the question becomes, is there therapeutic value in targeting a drug to that protein to reduce its production or block its function. Would that be an effective treatment?"

"We now want to correlate our discovery to patient samples using the human melanoma bank through our collaboration with Dr. Muriel Brackstone and other clinicians at the London Health Sciences Centre, to see if this is a cancer marker," added Penuela, a Postdoctoral Fellow working in the Laird lab.

"So if a melanoma lesion has a lot of this protein, it might be a tool for prognosis, in saying this is more advanced, or going to be highly metastatic. And because it's on the skin, it would be more accessible for treatment."

Penuela suggests potential treatment might be in the form of a topical medication to use on melanoma lesions.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

|

Story Source:

The above story is reprinted from materials provided by University of Western Ontario.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Stuart Endo-Streeter, Man-Kin Marco Tsui, Audrey R. Odom, Jeremy Block, and John D. York. Structural studies and protein engineering of inositol phosphate multikinase. J. Biol. Chem., August 15, 2012 DOI: 10.1074/jbc.M112.365031
APA

MLA

Note: If no author is given, the source is cited instead.

Search ScienceDaily

Number of stories in archives: 137,221

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

Recommend ScienceDaily on Facebook, Twitter, and Google:

Other social bookmarking and sharing services:

|

 
  more breaking science news

Social Networks


Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

|

Breaking News

... from NewsDaily.com

In Other News ...

Science Video News


Will Your Cancer Spread?

A new biopsy test, created by molecular biologists, can tell ocular melanoma patients if theirs is the kind that will spread. Using very thin. ...  > full story

Strange Science News

 

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Post this page to your favorite social bookmarking site:
Include this item in your blog or web site:
Cite this article in your essay, paper, or report:
Email this page's link to a friend or colleague: